5 completed, 1 not yet recruiting. 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 5, Not yet recruiting 1 |
Follow Cefiderocol: new trials by email Literature Review of Cefiderocol trials Research Report on Cefiderocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex BV100 with 50 mg polymyxin B plus ceftazidime/avibactam, BV100 with 50 mg polymyxin B plus cefiderocol, Best Available Therapy (BAT) - Ventilator Associated Bacterial Pneumonia (VABP), Hospital Acquired Bacterial Pneumonia (HABP) | Phase 2 | Not yet recruiting | BioVersys AG | 120 | 2026-07-01 | 2026-02-24 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants Cefiderocol, Standard of Care - Gram-Negative Bacterial Infections | Phase 2 | Completed | Shionogi | 30 | 2024-03-14 | 2026-03-02 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants Cefiderocol, Standard of Care - Gram-negative Bacterial Infections, Bloodstream Infections (BSI) | Phase 2 | Completed | Shionogi | 53 | 2020-08-21 | 2026-02-27 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants Cefiderocol, Standard of Care - Gram-negative Bacterial Infections, Hospital Acquired Bacterial Pneumonia (HABP) | Phase 2 | Completed | Shionogi | 91 | 2020-02-19 | 2025-05-25 |
| RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI Cefiderocol, Best Available Therapy - Bloodstream Infections | Phase 2 | Completed | The University of Queensland | 513 | 2019-10-28 | 2024-02-13 |
| A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections Cefiderocol, Imipenem/cilastatin - Urinary Tract Infections | Phase 2 | Completed | Shionogi | 452 | 2015-02-05 | 2019-12-12 |
Gram-Negative Bacterial Infections (3) · Sepsis (3) · Central Nervous System Infections (1) · Cerebral Ventriculitis (1) · Healthcare-Associated Pneumonia (1) · Meningitis, Bacterial (1) · Pneumonia, Ventilator-Associated (1) · Urinary Tract Infections (1)
Shionogi (4) · BioVersys AG (1) · The University of Queensland (1)
Australia (2) · Georgia (2) · Spain (2) · Taiwan (2) · Thailand (2) · Ukraine (2) · United States (2) · Belgium (1) · Estonia (1) · Greece (1) · Hungary (1) · Latvia (1) · Lithuania (1) · Malaysia (1) · Mexico (1)
PMID 39230271, PMID 30509675, PMID 33393598, PMID 34792787, PMID 34868583, PMID 34876196, PMID 41067237
2019 (2)